Therapeutic indications

Anagrelide is indicated for:

Essential thrombocythemia

Population group: both men and women, only adults (18 years old or older)

Anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.

An at risk patient

An at risk essential thrombocythaemia patient is defined by one or more of the following features:

  • >60 years of age or
  • a platelet count >1000 × 109/l or
  • a history of thrombo-haemorrhagic events.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Oral - 1-10 mg/day in two divided doses


Anagrelide is contraindicated in the following cases:

Moderate or severe renal impairment

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Moderate or severe hepatic impairment

at least one of
Hepatic failure stage II

Hepatic failure stage III

Hepatic failure stage IV

Medication Recommendation

Receive personalized medication regimen for every patient case

Ask the Reasoner

Related medicines